ERT to Acquire PHT Corporation
PHILADELPHIA and BOSTON – February 27, 2015 –– ERT, a leading global solution provider for high- quality patient safety and efficacy endpoint data collection, and PHT Corporation (PHT), the eClinical innovator leading the adoption of patient-driven mobile apps for improved clinical research, announced today that they have signed a definitive agreement under which ERT will acquire PHT. Financial terms of the transaction were not disclosed.
The transaction combines the flexible eCOA platform and world-class customer service of PHT with the leading clinical trial technology and service offerings of ERT, creating the most innovative and comprehensive solution for patient endpoint collection and data analytics for global clinical trials.
“We are thrilled to announce this strategic merger with PHT,” said Jim Corrigan, President and CEO of ERT. “This combination is about better serving our customers and delivering solutions to support the tremendous growth projected for the eCOA industry. By joining forces we are creating a truly innovative eCOA offering with global reach across therapeutic areas. Additionally, the transaction accelerates our strategy of innovating better health by becoming the software-enabled solution provider of choice; supporting clinical trials from early phase through regulatory submission and post-market research; and adding to our existing eCOA, respiratory, cardiac and data analytics portfolio.”
“This is a compelling combination that brings together two industry pioneers committed to using technology to transform clinical research and help bring new therapies to market,” said Philip Lee, President and CEO of PHT. “Our two companies share the same entrepreneurial drive, culture of innovation and unwavering focus on customer success and together we will be very well positioned to deliver best-in-class solutions to support patient-centric data collection in clinical trials.”
The combined company will have an increased global footprint throughout North America, Europe and in Asia, while serving all phases of clinical research for small and mid-sized biopharma to CROs and large pharmaceutical companies, including the top 30 pharmaceutical companies in the world. The combined scientific and regulatory expertise as well as the deep technical and operational teams in place will continue to bring innovative, patient-centric solutions to the clinical research industry.
The transaction is subject to regulatory review and is expected to close within the next several weeks.
About ERT
ERT (www.ert.com) is a leading provider of high-quality patient safety and efficacy endpoint data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services, and consulting that increase the accuracy and reliability of patient data and improve the efficiency of the clinical development process throughout the product lifecycle. ERT delivers the most widely deployed solutions in centralized cardiac safety, respiratory services, suicide risk assessment and Clinical Outcome Assessments (COAs) – which includes patient, clinician, and observer reported outcomes as well as data analytics across the trials. By efficiently integrating these solutions through a system built upon a scientific and regulatory foundation, ERT collects, analyzes, and delivers safety and efficacy data critical to the approval, labeling, and reimbursement of pharmaceutical products. ERT is a global organization with headquarters in Philadelphia, PA and offices throughout the U.S., U.K., Japan, and Germany.
About PHT Corporation
PHT Corporation is the eClinical innovator leading the adoption of patient-driven mobile apps for improved clinical research. The PHT electronic clinical outcome assessment (eCOA) system collects and reports secure real-time patient data from the latest mobile devices. PHT scientific, regulatory and technological expertise combined with quality outcomes data enable clients to make research decisions with confidence. Sponsors and CROs have leveraged the PHT Patient Suite in 750+ trials resulting in 22 regulatory approvals. PHT is headquartered in Boston and an office in Geneva.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
